Your browser doesn't support javascript.
Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E.
Zidi, Inès.
  • Zidi I; Laboratory Microorganismes and Active Biomolecules, Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia. Electronic address: ines.zidi@istmt.utm.tn.
Hum Immunol ; 81(12): 697-701, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-838428
ABSTRACT
SARS-CoV2 might conduce to rapid respiratory complications challenging healthcare systems worldwide. Immunological mechanisms associated to SARS-CoV2 infection are complex and not yet clearly elucidated. Arguments are in favour of a well host-adapted virus. Here I draw a systemic immunological representation linking actual SARS-CoV2 infection literature that hopefully might guide healthcare decisions to treat COVID-19. I suggest HLA-G and HLA-E, non classical HLA class I molecules, in the core of COVID-19 complications. These molecules are powerful in immune tolerance and might inhibit/suppress immune cells functions during SARS-CoV2 infection promoting virus subversion. Dosing soluble forms of these molecules in COVID-19 patients' plasma might help the identification of critical cases. I recommend also developing new SARS-CoV2 therapies based on the use of HLA-G and HLA-E or their specific receptors antibodies in combination with FDA approved therapeutics to combat efficiently COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Histocompatibility Antigens Class I / HLA-G Antigens / SARS-CoV-2 / COVID-19 Type of study: Observational study Limits: Humans Language: English Journal: Hum Immunol Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Histocompatibility Antigens Class I / HLA-G Antigens / SARS-CoV-2 / COVID-19 Type of study: Observational study Limits: Humans Language: English Journal: Hum Immunol Year: 2020 Document Type: Article